Figure 3. Multiple Sclerosis Relapse for Patients Treated With Dimethyl Fumarate (DMF) or Fingolimod (FGL) Based on Registry-Annotated Treatment Groups.

The lines depict the cumulative incidence curves for time to relapse, obtained from (A) Kaplan-Meier for crude estimation and (B) mean estimated relapse probability based on doubly robust (DR) estimation with adjustment of high-dimensional full electronic health record (EHR) features in addition to expert-defined features (based on clinical knowledge). The bars indicate the relapse rates at 1 year and 2 years since treatment initiation according to crude and DR analyses. Shaded areas and error bars indicate the 95% CIs. We reported the results based on the DR estimation in Table 2.